A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Key facts

Sponsor

Syndax Pharmaceuticals

Principal Investigator

Vedran Radojcic, M.D., CASAC

Syndax Pharmaceuticals

Intervention

Axatilimab(drug)

Enrollment

241 enrolled

Eligibility

2 years · All sexes

Timeline

2021 – 2027

Study locations (30)

• University of Alabama at Birmingham - Children's of Alabama, Birmingham, Alabama, United States
• University of Alabama at Birmingham, Birmingham, Alabama, United States
• City of Hope, Duarte, California, United States
• University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
• University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
• Stanford Cancer Center, Stanford, California, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• University of Florida (UF), Gainesville, Florida, United States
• Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
• University of Miami, Miami, Florida, United States
• AdventHealth Orlando, Orlando, Florida, United States
• Moffitt, Tampa, Florida, United States
• Emory University, Atlanta, Georgia, United States
• Northside Hospital, Atlanta, Georgia, United States
• The University of Chicago Medical Center (UCMC), Chicago, Illinois, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chronic graft versus host disease

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07394608
  Paired Non-invasive VNS in Adolescent Cerebral Palsy Rehabilitation
  Icahn School of Medicine at Mount Sinai
• RECRUITINGPHASE2NCT07124078
  A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
  Incyte Corporation
• RECRUITINGEARLY PHASE1NCT07355868
  Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy
  Regend Therapeutics
• RECRUITINGNANCT06857929
  "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition"
  IMDEA Food
• RECRUITINGPHASE1NCT07389044
  A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
  IntegerBio
• RECRUITINGNCT07127926
  Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT07138196
  A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
  Qurient Co., Ltd.
• ACTIVE NOT RECRUITINGNCT07321080
  Central Sensitisation in Nociceptive and Neuropathic Pain
  IRCCS Centro Neurolesi Bonino Pulejo

See all trials for Chronic graft versus host disease →